BioCryst shares are up over 12% to $10.90 on news that FDA has approved its flu vaccine to be used in hospitalized H1N1 patients. Option volume is running 6x the daily average with 29,000 call to 2,100 puts. Notable trades include block buying in later dated calls 4,400 of the Dec. $10 calls and 2,500 of the March $12.50 calls. The Dec/March $15 calendar traded 2,000 times in what looks like opening sale for 50c credit. Company slated to report earnings 10/29